DETAILED ACTION
Notice of Pre-AIA or AIA Status
The text of those sections of Title 35, U.S. Code not included in this action can
be found in a prior Office action.
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This action is in response to the papers filed on 09/09/2026. Claims 1, 7, 8, 14-17, 25-34 are currently pending as per claims filed on 09/09/2026. Claims 1, 7, 17, and 27 have been amended, Claims 32-34 have been newly added, and claims 4-6 have been cancelled by Applicants’ amendment filed on 09/09/2026.
Applicant’s election without traverse of Group I, claims 1, 4-8, 14-17 in the reply filed on 05/18/2026 was previously acknowledged.
Newly added claims 32-34, depends from claim 1 and claim 1 reads on the elected Group I, therefore claims 32-34 are being examined.
Claims 25, 26, and 28-31 were previously withdrawn from further
consideration by Applicants pursuant to 37 CFR 1.142(b), as being drawn to a
nonelected subject invention, there being no allowable generic or linking claim.
Therefore, claims 1, 7, 8, 14-17, and 32-34 are under examination to which the
following grounds of rejection are applicable. Claims 1 is an independent claim.
Priority
The present application is a 35 U.S.C. 371 national stage filing of International Application No. PCT/JP2022/007612 filed on 02/24/2022, which claims priority to Japanese Application 2021 031757, filed March 1, 2021. Filing of a certified translated copy of the Japanese Application 2021 031757, filed 09/09/2026 is acknowledged.
Thus, the earliest priority for the instant application is March 1, 2021.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 09/28/2026, was filed before the mailing date of the current office action. The submission is in compliance with the provisions of 37 CFR 1.97.
Accordingly, the information disclosure statement is being considered by the examiner.
Withdrawn objections/rejection in response to Applicants’ arguments or
Amendment
Claim Objections
In view of Applicant’s amendment of claim 1 spelling out FcɛRI, the claim objection has been withdrawn.
Claim Rejections - 35 USC § 112 (b)
In view of Applicant’s amendment of claim 17 adding “a polypeptide that is translated from” and removal of “produced based on”, the 112(b) rejection of claim 17 and 27 has been withdrawn.
In view of Applicant’s amendment of claim 17 adding “a γ-chain polypeptide of FcɛRI”, the 112(b) rejection of claim 17 and 27 has been withdrawn.
Claim Rejections - 35 USC § 103
In view of Applicant’s amendment of claim 1 to incorporate some of the limitations recited in claims 4-6 (now cancelled) which include:
the second base sequence encodes a transmembrane and intracellular domain,
a third base sequence encoding a signal sequence for expressing a chimeric FcɛRI-α-chain protein,
the transmembrane domain having 90% or more sequence identity to SEQ ID NO: 5
a base sequence corresponding to the intracellular domain having 90% or more sequence identity to SEQ ID NO: 6
the third base sequence comprises a base sequence corresponding to the signal sequence and having 90% or more sequence identity with SEQ ID NO: 2,
the rejection of claim(s) 1, 4-8, 14-17, and 27 under 35 U.S.C. 103 as being unpatentable over Dombrowicz et al (The Journal of Immunology, 1996, pages 1645-1651) and further in view of Macdonald et al (PNAS, 2014, pages 5147–5152), Jang et al (WO 2022019652 A1), Senoo et al (JP 2009050182 A), Kinet et al (Biochemistry, 1987, pages 4605-4610), Platzer et al (The Journal of Biological Chemistry, 2010, pages 15314-15323), Chakraborty et al (US 9220755 B2), and Nakamura et al (JP 2011019467 A; as cited in IDS) have been withdrawn.
Applicants’ arguments are moot in view of the withdrawn rejection.
Maintained and/or modified rejections in response to Applicants’ arguments or
Amendment
Claim Rejections - 35 USC § 112 (b)
Claim 27 remains rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. This is a modified rejection necessitated by amendments filed 09/09/2026.
Claim 27 is indefinite in its recitation of “wherein each of the two complexes is the complex”. It is not clear how each of the two complexes can simultaneously be “the complex”. In other words, it is unclear if the two complexes are the same complex. Appropriate correction is required
Claim Rejections - 35 USC § 112 (a)
Claim 1, 7, 8, 14-17 remain rejected and new claims 32-34 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a modified rejection necessitated by amendments filed 09/09/2026.
The claims are drawn to a chimeric FcɛRIα-chain gene comprising:
a first base sequence encoding an extracellular domain of a human FcɛRIα-chain
a second base sequence encoding at least a transmembrane domain and an intracellular domain of a non-human animal FcɛRIα -chain,
and a third base sequence encoding a signal sequence for expressing, on a cell membrane of a non-human animal cell, a chimeric FcɛRIα -chain protein generated based on the chimeric FcɛRIα -chain gene
wherein the first base sequence comprises a base sequence corresponding to the extracellular domain having 90% or more sequence identity with SEQ ID NO: 7
wherein the second base sequence comprises at least a base sequence corresponding to the transmembrane domain and having 90% or more sequence identity with SEQ ID NO: 5.
and a base sequence corresponding to the intracellular domain and having 90% or more sequence identity with SEQ ID NO: 6,
wherein the third base sequence comprises a base sequence corresponding to the signal sequence and having 90% or more sequence identity with SEQ ID NO: 2, and
wherein expression of the chimeric FcɛRIα -chain gene in a cell of the non- human animal results in production of a chimeric FcɛRIα -chain protein, and the chimeric FcɛRIα -chain protein forms a complex with at least FcɛRI γ-chain protein of the non-human animal.
With the exception of 7 constructs ("HuRa-11", "HuRa-19", "HuRa-21", "HuRa-29", "HuRa-37", "HuRa-38", and "HuRa-40" (specification Figure 7, para 0212) encoding the entire chimeric FcɛRIα -chain gene, all of which are interpreted to be the full sequence set forth in SEQ ID NO: 1 as the specification only discloses that the examples are of SEQ ID NO: 1 (para 0186, para 0193, para 0205, and Figure 4), the Applicant’s do not describe a representative number of species of the broadly claimed genus of first, second, and third base sequences each with 90% or more sequence identity to SEQ ID NO: 7, SEQ ID NO: 5/6, and SEQ ID NO: 2, respectively. Similarly, Applicant’s do not describe a representative number of species of the broadly claimed genus of chimeric FcɛRIα -chain gene that has a base sequence having 90% or more sequence identity to SEQ ID NO: 1 (claim 7) . Rather, the specification only provides working examples of generating 7 constructs comprising a chimeric FcɛRIα -chain gene and wherein the chimeric FcɛRIα -chain gene comprises the full nucleotide sequence of SEQ ID NO:1 and demonstrate the ability to induce a reporter gene (luciferase). Indeed, SEQ ID NO: 1 comprises, as shown in Figure 19 below:
The first base sequence (extracellular domain) set forth in SEQ ID NO: 7 which functions as an IgE binding region (para 0041)
The second base sequence (transmembrane domain) set forth in SEQ ID NO: 5 which functions as a γ-chain binding domain (para 0049)
The second base sequence further comprising sequence set forth in SEQ ID NO: 6 (intracellular domain) and,
A third base sequence set forth in SEQ ID NO: 2 (signal sequence)
PNG
media_image1.png
404
871
media_image1.png
Greyscale
red = SEQ ID NO: 2, purple = SEQ ID NO: 7, green = SEQ ID NO: 5, yellow = SEQ ID NO: 6
With the exception of the full-length chimeric FcɛRIα encoded by the chain gene of SEQ ID NO:1 and its components (including extracellular domain set forth in SEQ ID NO: 7, transmembrane domain set for in SEQ ID NO: 5, intracellular domain set forth in
SEQ ID NO: 6, and signal sequence set forth in SEQ ID NO: 2), Applicants have not described any other polynucleotides which have at least 90% identity to SEQ ID NO:1 and 90% identity to any of the nucleotides identified by the SEQ IDs for each respective component of the chimeric FcɛRIα -chain gene and which, when expressed in all possible cells, confer the phenotype of complexing with the γ-chain of the FcɛRI cell and inducing expression of a reporter gene when complexed/crosslinked. Applicants fail to specifically describe any other possible polynucleotide from the broadly claimed genus of polynucleotides having at least 90% identity to SEQ ID NO:1 and 90% identity to the SEQ IDs for each respective component of the chimeric FcɛRIα -chain gene such that it would the confer the phenotype of complexing with the γ-chain of the FcɛRI cell and inducing expression of a reporter gene when complexed/crosslinked in all cells.
This disclosure is not deemed to be descriptive of the complete structure of a representative number of species encompassed by the claims as one of skill in the art cannot envision all the fragments having complexing with the γ-chain of the FcɛRI cell and inducing expression of a reporter gene when complexed/crosslinked in the cell based on the teachings in the specification.
As discussed in MPEP 2163(I)(A), “a biomolecule sequence described only by a functional characteristic, without any known or disclosed correlation between that function and the structure of the sequence, normally is not a sufficient identifying characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence”
Moreover, the instant Specification fails to provide guidance for which nucleotides of SEQ ID NO:1, 2, 5, 6, and 7 can be substituted, and to which nucleotides, and also which nucleotides must not be changed, to maintain the functional activity of the encoded gene. The Specification also fails to provide guidance for which nucleotides can be deleted and which regions of the gene can tolerate insertions and/or additions and still produce a functional protein. Describing and reducing to practice the claimed genus of nucleotide substitutions/deletions/insertions in the gene of SEQ ID NO:1, 2, 5, 6, and 7 is unpredictable. While it is known that many nucleotide substitutions, additions or deletions are generally possible in any given gene, the positions within the gene’s sequence where the resulting amino acid changes can be made with a reasonable expectation of success (without altering protein function) are limited. Certain positions in the sequence are critical to the protein’s structure/function. (see Ngo, in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495, 1994; as cited in office action 09/09/2026). Rudinger (in Peptide Hormones, Parsons (ed.), University Park Press: Baltimore, MD, pp. 1-7, 1976 as cited in office action 09/09/2026) discloses that even for peptide hormones, which are much smaller than the instant FcɛRI α-chain, one cannot predict variant amino acid sequences for a biologically active polypeptide. As an example, related to sequence modifications for Fc receptor genes, it is known that a single nucleotide change in exon 4 in FcγRIIa gene leads to an arginine (R) to histidine (H) change and can alter the receptor affinity for its ligand, thus altering its functionality. Similarly, some SNPs in the FcR cluster can affect the signaling capacity of the expressed receptor (see Human FcR Polymorphism and Disease, Li, 2014, page 276 and 281; as cited in office action 09/09/2026).
To put the situation in perspective, claim 7 recites any gene that is 90% similar to the base sequence of SEQ ID NO:1 (SEQ ID NO: 7 is 741 base pairs). That 90 percent variance results in a situation in which even if a 74 contiguous nucleotide region is independently varied among the 4 different nucleotides (744), there would be 29,986,576 possible combinations. In fact, since the variation could occur at any position, the actual number of different molecules is orders of magnitude greater than 29,986,576. Thus, the Specification fails to overcome the unpredictability of reducing to practice the large numbers of nucleotide deletions/substitutions/insertions/additions in the gene of SEQ ID NO:1, 2, 5, 6, and 7 and still retain the contemplated function as it does not provide an adequate description of the gene with the recited nucleotide substitutions relative to SEQ ID NO:1, 2, 5, 6, and 7 and there is an extremely large genus of possible combinations for just SEQ ID NO:1.
The Specification fails to provide an adequate written description to support the breadth of the claims as only one chimeric FcɛRI α-chain gene is disclosed (SEQ ID NO: 1). Therefore, the specification does not describe the claimed fragments in such full, clear, concise and exact terms so as to indicate that Applicant has possession of these fragments at the time of filing the present application. Thus, it is concluded that the written description requirement is not satisfied for the claimed genera.
Scope of Enablement
Claim 1, 7, 8, 14-17, and 32-34 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for
a chimeric FcɛRI α-chain gene comprising a sequence set forth in SEQ ID NO: 1 which comprises:
The first base sequence (extracellular domain) set forth in SEQ ID NO: 7 which functions as an IgE binding region (para 0041)
The second base sequence (transmembrane domain) set forth in SEQ ID NO: 5 which functions as a γ-chain binding domain (para 0049)
The second base sequence further comprising sequence set forth in SEQ ID NO: 6 (intracellular domain) and,
A third base sequence set forth in SEQ ID NO: 2 (signal sequence)
Does not reasonably provide enablement for:
a first base sequence encoding an extracellular domain of a human FcɛRIα-chain having 90% or more sequence identity ·with SEQ ID NO: 7
a second base sequence encoding at least a transmembrane domain having 90% or more sequence identity with SEQ ID NO: 5.
and an intracellular domain of a non-human animal FcɛRIα -chain having 90% or more sequence identity with SEQ ID NO: 6,
and a third base sequence encoding a signal sequence for expressing, on a cell membrane of a non-human animal cell, a chimeric FcɛRIα -chain protein generated based on the chimeric FcɛRIα -chain gene having 90% or more sequence identity with SEQ ID NO: 2
and wherein expression of the chimeric FcɛRIα -chain gene in a cell of the non- human animal results in production of a chimeric FcɛRIα -chain protein, and the chimeric FcɛRIα -chain protein forms a complex with at least FcɛRI γ-chain protein of the non-human animal.
The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.
The factors to be considered in determining whether undue experimentation is required are summarized in In re Wands, 858 F.2d 731, 737, 8 U.S.P.Q.2d 1400, 1404 (Fed. Cir. 1988) (a) the breadth of the claims; (b) the nature of the invention; (c) the state of the prior art; (d) the level of one of ordinary skill; (e) the level of predictability in the art; (f) the amount of direction provided by the inventor; (g) the existence of working examples; and (h) the quantity of experimentation needed to make or use the invention based on the content of the disclosure. While all of these factors are considered, a sufficient number are discussed below so as to create a prima facie case.
the breadth of the claims; the nature of the invention:
The claims are drawn to a vast genus of chimeric FcɛRIα-chain genes comprising a first base sequence comprises a base sequence having 90% or more sequence identity with SEQ ID NO: 7, a second base sequence comprises at least a base sequence having 90% or more sequence identity with SEQ ID NO: 5 and further comprises a base sequence having 90% or more sequence identity with SEQ ID NO: 6, A third base sequence comprising a base sequence having 90% or more sequence identity with SEQ ID NO: 2, and wherein the chimeric FcɛRIα -chain gene has a base sequence having 90% or more sequence identity with SEQ ID NO: 1.
The claims broadly encompass any nucleotide substitution/deletion/insertion for the chimeric FcɛRI-α chain gene such that there is at least 90% or more identity to SEQ ID NO: 2, 5, 6, and 7 and at least 90% or more identity to SEQ ID NO: 1 and such that the chimeric FcɛRI-α chain gene can perform the claimed function of complexing with the γ-chain of the FcɛRI of the cell. Thus, the claims are directed to a large genus of chimeric FcɛRI-α chain genes that could comprise a vast array of nucleotide sequences that result in a gene product capable of complexing the the γ-chain of FcɛRI and induce expression of any reporter gene in any cell.
the amount of direction provided by the inventor; the existence of working examples:
However, the specification does not disclose a reduction to practice of chimeric FcɛRI-α chain gene other than a chimeric FcɛRI-α chain gene sequence set forth in SEQ ID NO: 1, which comprises the components: extracellular domain set forth in SEQ ID NO: 7, transmembrane domain set for in SEQ ID NO: 5, intracellular domain set forth in SEQ ID NO: 6, and signal sequence set forth in SEQ ID NO: 2. The specification does not disclose if any other nucleotide sequences, besides those aforementioned, would permit the translation of the corresponding protein sequence of the FcɛRI-α chain gene and thus exhibit the phenotype of complexing with the γ-chain of FcɛRI and inducing reporter gene expression in any cell. The specification only contemplates that the chimeric FcɛRI-α chain with at least 90% or more identity to SEQ ID NO: 2, 5, 6, and 7 and at least 90% or more identity to SEQ ID NO: 1 can perform the claimed function of complexing with the γ-chain of the FcɛRI of the cell and inducing reporter gene expression in any cell.
the state of the prior art; the level of predictability in the art:
It is known in the art that even conservative amino acid substitutions, which ultimately arise from modifications of a corresponding nucleic acid sequence, can adversely affect proper folding and biological activity if amino acids that are critical for such functions are substituted, and the relationship between the sequence of a polypeptide and its tertiary structure is neither well understood nor predictable (see Ngo, in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495, 1994). Rudinger (in Peptide Hormones, Parsons (ed.), University Park Press: Baltimore, MD, pp. 1-7, 1976) discloses that even for peptide hormones, which are much smaller than the instant FcɛRI α-chain, one cannot predict variant amino acid sequences for a biologically active polypeptide. Rather one must engage in "case to case painstaking experimental study" to determine active variants (see page 7). It is known that Human Fc receptor polymorphisms exist and the vast array of polymorphisms have functional implications. For example, a single nucleotide polymorphisms (SNP) in exon 4 in FcγRIIa gene leads to an arginine (R) to histidine (H) change and can alter the receptor affinity for its ligand, thus altering its functionality. Similarly, some SNPs in the FcR cluster can affect the signaling capacity of the expressed receptor (see Human FcR Polymorphism and Disease, Li, 2014, page 276 and 281).
Hence, modifications in the sequence corresponding to the FcɛRI-α chain gene, including all of its components, and corresponding phenotype of complexing with the γ-chain and inducing reporter gene expression in a cell is not necessarily predictable.
The quantity of experimentation needed to make or use the invention based on the content of the disclosure:
The skilled artisan would be required to perform under levels of experimentation in order to practice the claimed invention. The instant specification does not reduce to practice the claimed invention; the instant specification does not provide guidance on how to reasonably predict which nucleotides for each of the SEQ ID NOs 1, 2, 5, 6, and 7 should be mutated to gain the desired phenotype of complexing the FcɛRIα-chain with the γ-chain and inducing reporter gene expression upon complexing. Excessive trial and error experimentation would have been required to identify the necessary derivatives for the entire FcɛRI-α chain gene with an activity of SEQ ID NO: 1, as well as the activity for the derivatives for each of the FcɛRI-α chain gene components (i.e. SEQ ID 2, 5, 6, and 7) and since the amino acid sequence resulting from the polynucleotide sequences could not be predicted - even were the activity known.
The level of one of ordinary skill:
The level of one of ordinary skill is a PhD holder.
Conclusion
When all of the Wands factors are considered together, they establish a prima facie case that the specification is not enabling for the claims. The specification only provides details for the FcɛRI-α chain gene corresponding to SEQ ID NO:1, which comprises the components: SEQ ID NO: 2, 5, 6, and 7, and which can form a complex with the γ-chain and induce reporter gene expression function in a cell. While a lack of a working embodiment cannot be a sole factor in determining enablement, the lack of any working examples, in light of the unpredictable nature of the art and the lack of direction applicants present, provides additional weight to the lack of enablement in consideration of the Wands factors as a whole. Thus, one of ordinary skill in the art would not have had a reasonable expectation of success in making or using the claimed invention.
Response to Applicant’s arguments as they apply to rejection of claims 1, 7, 8, 14-17, and 32-34 under 35 USC § 112(a)
Applicant’s arguments filed 09/09/2026 have been fully considered but not persuasive.
Applicant asserts that 1) the present specification provides detailed explanation on the functions of the four components recited in amended Claim 1 and the function of the protein, therefore the present specification teaches regions and domains of the protein that are important for the claimed activity, 2) it was common technical knowledge that multiple distinct nucleotide sequences can encode the same amino acid sequence, that insertion/deletion of nucleotides may drastically change a polypeptide, and that one of ordinary skill in the art would know what type of nucleotide changes can be made while maintaining function
Regarding argument 1) and 2), the Examiner submits that, while the specification provides an explanation of the function for each of the four domains (first base sequence encoding the extracellular domain (paras. [0040]-[0041]); the second base sequence encoding the transmembrane domain and the intracellular domain (paras. [0049]-[0052]); and the third base sequence encoding the signal sequence (paras. [0060]-[0061]) and the relationship between the structure and the function of each domain (paras. [0184]-[0276], the descriptions ultimately fails to disclose particular nucleic acid positions and corresponding amino acid positions and residues that are imperative to maintaining the function of being able to complex with at least one FcɛRI γ-chain protein in a non-human animal. For example, para [0188] recites which residues at particular positions are involved in the IgE-binding region, however there are no suggestions for one of ordinary skill in the art to know what alternative amino acid residue, and equivalent nucleotide sequence, would be sufficient to maintain the structure of the IgE-binding region. In other words, the specification fails to disclose how one of ordinary skill in the art would be able to discern which changes in the nucleotide sequence, and resulting amino acid residue, could effectively maintain the function of each domain and subsequently confer the function of complexing with at least one FcɛRI γ-chain protein in a non-human animal. The lack of any working examples of any alternative sequences besides SEQ ID NO:1 for the entire FcɛRI α-chain and SEQ ID NOs: 2, 5, 6, and 7 for each respective domain further reiterates the basis for the written description and enablement rejections.
Regarding Applicant’s argument pertaining changes in nucleotide sequences to encode the same amino acid sequence and that sequence modifications for FcɛRI subunits have been previously demonstrated to be successful, while it is understood that different nucleotides within a codon can give rise to equivalent amino acids, it is the shear amount of nucleotide sequence alterations and combinations that could be made across the 4 domains and the high amount of testing required to determine the FcɛRI α-chain complexing ability and the impact of each modification at each domain, as recited above in the 112(a) rejection, which would be a burdensome to one of ordinary skill in the art. Similarly, Applicant acknowledges that the attached art of Mallamaci and Hulett indeed teach that certain modifications in FcɛRIα change binding ability, further indicating that there could be a certain level of change to functionality to the receptor, albeit not always completely nonfunctional. However, these modifications of Mallamaci and Hulett in FcɛRIα are not recited in the instant claims having variants of an extracellular domain of a human FceRI a chain~ having 90% sequence homology to SEQ ID NO:7 or variants of a transmembrane domain and an intracellular domain having 90% sequence homology to the sequence identified as SEQ ID NOS 5 or 6.
Applicant asserts that the present specification would allow one of ordinary skill in the art to understand which nucleotides can be substituted, but there are not working examples of any specific positions in any of the sequences that can be changed and shown to maintain functionality. Therefore, in conclusion, the Applicant remains failing to meet the written description and scope of enablement requirements.
Conclusion
No claims are allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliana Candelaria whose telephone number is (571)272-5488. The examiner can normally be reached Monday - Friday 8am - 5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached at (571) 272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JULIANA IRENE CANDELARIA/Examiner, Art Unit 1634
/MARIA G LEAVITT/Supervisory Patent Examiner, Art Unit 1634